News, Events & Resources
There’s a lot happening at Melinta. We are the company of the moment and enterprise of the future. Join us in realizing our vision — this is our story, and it’s going to be legendary.
Melinta Joins NHIA Future of Infusion Advisory Council
For Melinta, membership in the FIAC provides the opportunity for critical collaboration with the association and other organizations serving patients requiring infusion therapies. This work helps to enhance continuity of care as patients transition out of the hospital.
Melinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ (oritavancin)
KIMYRSA™ Receives Product-Specific J-Code and Transitional Pass-Through Status from CMS
Melinta Therapeutics Announces Appointment of Jisoo Park as Head of Business Development, M&A and Strategy
Jisoo Park, a leader in global pharmaceutical business development, joins Melinta under the leadership of President and Chief Executive Officer Christine Ann Miller.
Melinta Therapeutics Announces Commercial Availability of KIMYRSA™ (oritavancin)
-Single-Dose Antibiotic with One-Hour Infusion, Additional Compatibilities in Normal Saline and D5W, and Lower Infusion Volume-